LXRP - Lexaria Bioscience Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
1.83
-0.06 (-3.05%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.89
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume262,025
Market Cap131.343M
Beta2.88
PE Ratio (TTM)N/A
EPS (TTM)-0.05
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Lexaria DehydraTECH Shows Promise in Nervous System Disorders -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Lexaria Biosciences Inc. (CSE:LXX) (LXX.CN) (CNSX:LXX) (LXRP), which originally developed its DehydraTECH™ platform to increase the bioavailability of cannabinoids. The company has since broadened its focus well-beyond the cannabis industry. A recent discovery suggests that the proprietary platform may be effective in enabling researchers to deliver APIs past the blood brain barrier.

  • ACCESSWIRE13 days ago

    Lexaria Announces 2018 AGM Results and Corporate Update

    KELOWNA, BC / ACCESSWIRE / July 3, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special ...

  • ACCESSWIRE17 days ago

    Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders

    KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / June 29, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has filed an important new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more. In recent laboratory testing, Lexaria's breakthrough discovery evidenced greatly enhanced drug delivery to brain tissue. Nicotine in-vivo (animal) studies showed that up to 560% more nicotine was delivered to brain tissue utilizing DehydraTECHTM than concentration-matched controls lacking DehydraTECHTM enhancements.

  • GlobeNewswire20 days ago

    Lexaria's DehydraTECH Overcomes Key Hurdles for Cannabis Extracts -- CFN Media

    The company addresses the shortcomings of precise dosing across a wide range of delivery systems with its DehydraTECH™ drug delivery platform. By combining cannabinoids with fatty acid oil, applying food carrier particles, and performing a dehydration procedure, the technology masks the bitter and earthy taste of cannabis oil and ensures quick and effective transportation into the bloodstream without degradation in the stomach or liver. Lexaria’s technology now has over 40 patents pending and four patents already granted in the US.

  • GlobeNewswire2 months ago

    CFN Media's Exclusive Interview With Lexaria Bioscience CEO Chris Bunka

    The company is paving the road in terms of cannabinoid delivery research and development. CFN Media spoke with Lexaria CEO Chris Bunka at the recent MJBizNEXT Conference in New Orleans to learn more about the firm’s innovation and their plans to dramatically change the way people think about cannabis.

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Corp. Structures Nicotine & Pharmaceutical Subsidiaries

    KELOWNA, BC / ACCESSWIRE / May 31, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that, subject to ongoing legal and tax analysis, it intends to create two wholly-owned subsidiaries that will respectively hold the intellectual property (''IP'') related to, in the case of the first subsidiary, the improved processing and combustion-free delivery of nicotine and nicotine analogs and, in the case of the second subsidiary, delivery of non-steroidal anti-inflammatory drugs (''NSAIDs''), phosphodiesterase (''PDE5'') inhibitors and other active pharmaceutical ingredients. This proposed structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each.

  • ACCESSWIRE2 months ago

    Lexaria Announces Exercises of Existing Warrants, Enters Consulting Agreement

    KELOWNA, B.C. / ACCESSWIRE / May 28, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces warrant transactions. Lexaria announces it has received US$63,000 from the exercise of warrants previously granted. The Company has received for exercise a total of 450,000 warrants with an exercise price of US$0.14, previously granted.

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Corp. Receives New Granted Patents

    KELOWNA, BC / ACCESSWIRE / May 23, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received notifications that it has received two new US patents granted and additionally expects three new Australian patents granted on or before August 17th. Once granted, Lexaria will have 4 granted patents in the US and 4 granted patents in Australia. All eight of these patents are within Lexaria's first patent family, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof", and significantly strengthen Lexaria's intellectual property ("IP") claims in the US and Australia.

  • GlobeNewswire2 months ago

    Lexaria Solidifies Presence in Edibles Market with New Agreement -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Bioscience Corp.’s  (LXX.CN) (LXX.CN) (LXX.CN) (LXRP) DehydraTECH™ platform which enables edibles manufacturers to increase bioavailability, improve flavor profiles, and expedite the onset of cannabinoid effects across a wide range of products. Investors may want to take note of the stock since the company’s growing number of licensees represents an attractive way to build exposure to edibles through royalty-based licensing agreements. The cannabis industry is projected to reach $50 billion by 2026, according to Cowen & Co., driven by the legalization of adult-use cannabis across many states.

  • GlobeNewswire2 months ago

    Lexaria’s DehydraTECH Builds Market Share in Cannabis Beverage Industry -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Bioscience Corp's. The cannabis industry is expected to reach $50 billion by 2026 in the U.S. and C$22.6 billion over the coming years in Canada, according to industry analysts. While cannabis flower still commands the most sales, cannabis-infused products have become the fastest-growing segment across North America.

  • GlobeNewswire2 months ago

    Lexaria Technology Brings "Fast-Acting" to Nuka’s 1906 Cannabis Products with 10-Year Deal Consummating Proof-of-Concept Relationship

    KELOWNA, British Columbia, April 30, 2018-- via NetworkWire-- Lexaria Bioscience Corp., an innovator in drug delivery platforms, today announced a major new licensing agreement with Nuka Enterprises LLC, ...

  • GlobeNewswire3 months ago

    NetworkNewsWire Announces Publication on Innovative Cannabis and Nicotine Delivery Technology

    NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- via NetworkWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE:LXX) (LXRP), a client of NNW focused on developing and out-licensing its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids and nicotine. Lexaria`s patented DehydraTECH delivery technology provides a complementary layer suitable for a versatile range of commercial applications, allowing for a potentially healthier alternative to smoking or vaping practices for both cannabis and nicotine users. With more than 35 patents pending in over 40 countries, Lexaria is the only company in the world with a patent in the United States and Australia for the improved (oral or ingestible) delivery of all nonpsychoactive cannabinoids.

  • ACCESSWIRE3 months ago

    Lexaria Announces LOI with Hill Street Beverage Co. for Cannabis Infused Alcohol-Free Beer and Wine

    KELOWNA, BC / ACCESSWIRE / April 27, 2018 / Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has entered a Letter of Intent (the "LOI") with Hill Street Beverage Co. to license DehydraTECH TM, on a semi exclusive basis to produce a line of cannabis infused alcohol-free beers and wines for Canadian distribution, following regulatory approval. The LOI is currently non-binding and is subject to the parties entering into a definitive binding agreement, which is expected to occur in the latter part of 2018. Lexaria has already lab-tested Hill Street's alcohol-free red and white wines to formulate CBD wines from multi-spectrum hemp oil, and such tests show virtually zero unwanted cannabis taste or odour.

  • GlobeNewswire3 months ago

    NetworkNewsWire Announces Publication on Good News in Biotech Advancements Through Cannabis Delivery Technology

    NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE:LXX) (LXRP), a client of NNW that has developed and out-licenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria’s ingestible nicotine study using DehydraTECH delivered nicotine to the bloodstream within 15 minutes, provided an increased gain of 148 percent of peak nicotine to the bloodstream and produced 560 percent higher brain levels of nicotine, where the nicotine’s effects are focused. Lower urine levels of nicotine were also noted, signifying enhanced nicotine activity and bioavailability, and lower quantities of key liver metabolites were found in the bloodstream, suggesting bypass of first liver metabolism.

  • ACCESSWIRE3 months ago

    Lexaria Enters Definitive License Agreement with California Cannabis Beverage Manufacturer

    KELOWNA, BC / ACCESSWIRE / April 25, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered ...

  • GlobeNewswire3 months ago

    Lexaria Achieves Breakthrough in $21.8 Billion Smoking Cessation Industry -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Bioscience Corp. (LXX.CN) (LXX.CN) (LXX.CN) (LXRP), developer of the DehyraTECH™ platform for improving the bioavailability of active pharmaceutical ingredients (APIs). The company recently unveiled positive results from its trials involving nicotine, which could pave the way for its entry into the large and growing nicotine replacement industry.

  • ACCESSWIRE3 months ago

    Lexaria Announces Human Clinical Study on CBD Absorption Underway

    KELOWNA, BC / ACCESSWIRE / April 23, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce that it has commenced ...

  • Newsfile3 months ago

    NetworkNewsAudio Covers Lexaria's Biotech Breakthrough in Nicotine Delivery

    New York, New York--(Newsfile Corp. - April 20, 2018) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for business, today announces the audio version of the Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recent press release titled "Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology."To hear the Lexaria AudioPressRelease (APR) version, visit: http://nnw.fm/cJ6e5To read the original press release, visit: http://nnw.fm/u4DbMAbout Lexaria Bioscience Corp.Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that ...

  • GlobeNewswire3 months ago

    NetworkNewsAudio Covers Lexaria’s Biotech Breakthrough in Nicotine Delivery

    NEW YORK, April 20, 2018-- via NetworkWire– NetworkNewsWire, a multifaceted financial news and publishing company for business, today announces the audio version of the Lexaria Bioscience Corp. recent ...

  • GlobeNewswire3 months ago

    Why Lexaria’s Patents Represent a Big Opportunity — CFN Media

    SEATTLE, April 18, 2018-- CFN Media Group, the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Biosciences ...

  • ACCESSWIRE3 months ago

    Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology

    KELOWNA, BC / ACCESSWIRE / April 17, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce ...

  • ACCESSWIRE3 months ago

    Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for Cannabinoid Delivery and Updates Its Expanding Patent Portfolio

    KELOWNA, BC / ACCESSWIRE / April 11, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received ...

  • Newsfile3 months ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Innovative Cannabinoid Applications

    New York, New York--(Newsfile Corp. - April 5, 2018) - CannabisNewsAudio announces the Audio Press Release (APR) titled "Infusion of Biotechnology into Cannabis Market Leads to Booming Growth," featuring Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX).To hear the NetworkNewsAudio version, visit: http://nnw.fm/jhN9bTo read the original editorial, visit: http://cnw.fm/prTG5The company is also exploring the use of DehydraTECH in the absorption of drugs through the skin. Lexaria has recently filed a new patent to improve the ...